Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy and safety results from a phase 2 study

Authors

H L.A. Janssen
P Lampertico
C-H Chen
J Heo
C Fournier
S H. Ahn
T Y.O. Tsang
C S. Coffin
Y-H Huang
G M. Reggiani
A J. Hui
M Elkhashab
C-Y Chen
Syed-Mohammed Jafri, Henry Ford HealthFollow
S Tan
Y Zhao
V Suri
J F. Flaherty
A Gaggar
D Brainard
W-L Chuang
K Agarwal
E Gane
Y-S Lim

Recommended Citation

Janssen HLA, Lampertico P, Chen C-H, Heo J, Fournier C, Ahn SH, Tsang TYO, Coffin CS, Huang Y-H, Reggiani GM, Hui AJ, Elkhashab M, Chen C-Y, Jafri S-M, Tan S, Zhao Y, Suri V, Flaherty JF, Gaggar A, Brainard D, Chuang W-L, Agarwal K, Gane E, and Lim Y-S. Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy and safety results from a phase 2 study. J Hepatol 2021; 75:S756-S757.

Document Type

Conference Proceeding

Publication Date

7-1-2021

Publication Title

J Hepatol

Volume

75

Issue

Suppl 2

First Page

S756

Last Page

S757